Navigating Neuropsychology cover image

97| Medications for Memory Loss in Older Adults – A Conversation With Dr. Matthew Growdon

Navigating Neuropsychology

00:00

The FDA Approval of Aducanumab Aduhelm

Aducanumab Aduhelm is in this new class of anti-amyloid antibodies that theoretically should have more of a disease modifying effect. The trials showed actually a fair bit of side effect and not like minor side effect but like things where people needed to be you know monitor very closely for brain swelling related to the therapy. I think it scares me potentially in the real world that we just need to make sure that if these things are being used by a large number of people that there are really good systems to catch them  to make sure that they're safe.

Transcript
Play full episode

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app